Faheem Hasnain is the President, Chief Executive Officer, and Chairman of Gossamer Bio, Inc., a biopharmaceutical company focused on immunology and inflammation. He has deep roots in the biotech world, being a co-founder of Gossamer and serving as its CEO...

Faheem Hasnain is the President, Chief Executive Officer, and Chairman of Gossamer Bio, Inc., a biopharmaceutical company focused on immunology and inflammation. He has deep roots in the biotech world, being a co-founder of Gossamer and serving as its CEO since November 2020, after transitioning from Executive Chairman. Before joining Gossamer, Hasnain led Receptos as President and CEO, taking the company through its acquisition by Celgene. His journey is marked by significant achievements in clinical development and regulatory milestones, showing a hands-on approach to leadership. Under his guidance, Gossamer has emphasized aligning executive compensation with performance, which is key in the competitive biopharma space. In 2023, he earned nearly $2.1 million, with a substantial bonus reflecting corporate performance goals. Notably, during his tenure, the company's market value has seen fluctuations, highlighting the dynamic nature of the industry. Hasnain's leadership style combines strategic vision with a focus on results, making him a driving force at Gossamer Bio.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Gossamer Bio, Inc. CEOs

G

Faheem Hasnain

Founder and CEO of Gossamer Bio, Inc.

Education

B.H.K. and B.Ed. from the University of Windsor Ontario

Field of Expertise

Healthcare & Life Sciences - Biopharmaceuticals

Sector of Economy

Healthcare

CEO of Gossamer Bio, Inc. for

4 years 4 months (Nov 2020 - Present)

Previous Experience

President and CEO of Receptos

Rivals

Competitors/colleagues of Faheem Hasnain

Holdings

See how much did Faheem Hasnain make over time.

Faheem Hasnain's holdings in Gossamer Bio have fluctuated significantly over the years. At their peak in late 2021, his stock holdings were valued around $5.6 million. Since then, the value has seen ups and downs, reflecting the changing landscape of...

Faheem Hasnain's holdings in Gossamer Bio have fluctuated significantly over the years. At their peak in late 2021, his stock holdings were valued around $5.6 million. Since then, the value has seen ups and downs, reflecting the changing landscape of biotech stocks. As of early 2023, Hasnain actively traded his shares, with values dropping to as low as $8.54 million in January but managing to recover somewhat with holdings around $5 million by late 2023. These fluctuations underscore how tightly his wealth is tied to the company's performance and market movements. His experience in managing these holdings highlights his familiarity with the unpredictable nature of biotech investments and the critical role of patient, strategic planning amid market volatility.

Total Stock Sold

$194.62K

GOSS

$194.62K

42,207 GOSS shares

What if they kept their stock?

If Faheem Hasnain didn't sell their stock, today they would have:
Extra GOSS42,207 shares worth $482.85K.
This is 148.1% and $288.23K more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Faheem Hasnain.

GOSS

$250.28K

GOSS at $0.67/share

Jun 21, 2024

Purchase

GOSS

$26.77K

GOSS at $1.16/share

Mar 27, 2024

Sale

GOSS

$983.12K

GOSS at $1.82/share

Jul 24, 2023

Received

GOSS

$988.13K

GOSS at $1.12/share

Mar 20, 2023

Purchase

GOSS

$1.00M

GOSS at $7.21/share

Jul 15, 2022

Purchase

GOSS

$169.70K

GOSS at $8.92/share

Mar 23, 2022

Sale

GOSS

162,500 shares

GOSS

Feb 25, 2021

Received

NUVB

$300.00K

NUVB at $10.00/share

Feb 10, 2021

Received

GOSS

$1.00M

GOSS at $10.36/share

Oct 14, 2020

Purchase

GOSS

$167.98K

GOSS at $16.80/share

Sep 27, 2019

Purchase

Compensation History

See how much did Faheem Hasnain make over time.

Faheem Hasnain's compensation reflects his role in guiding Gossamer Bio through crucial growth phases. In 2023, he received a total package worth approximately $2.1 million. This includes a base salary of about $607,000, a hefty bonus of $1.2 million based on achieving key corporate goals, and additional benefits worth around $303,000. Notably, no stock or options vested in the last year, as the company has focused on cash compensation to drive performance. From 2021 to 2023, his total compensation has increased significantly, demonstrating the board's commitment to aligning pay with the company's success. His structure incentivizes strong performance while keeping a reasoned approach to managing the company's financial resources.

Year

2023

Total Compensation

$2.10M

Salary

$606.90K

Board Justification

The compensation philosophy aims to attract, engage, and retain an executive team by providing competitive total pay opportunities linked to company performance.

Bonus

$1.19M

Board Justification

Based on the achievement of corporate performance goals during 2023, the annual incentives tied to corporate performance were paid out at 90% of target.

Other

$303.36K

Board Justification

Includes company-paid 401(k) matching contributions and other benefits.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock awards vested in 2023 as the focus is on cash compensation and performance bonuses.

Performance Metrics

Corporate performance goals tied to clinical and regulatory development of seralutinib and certain quality and finance measures.

Other Gossamer Bio, Inc. CEOs

Here are other CEOs of Gossamer Bio, Inc.

Sheila Gujrathi, M.D.

Ex-CEO of Gossamer Bio, Inc.

January 2018 - November 2020